Weihua Chen

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.

Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.

Journal: Human mutation

Published: February 07, 2026

Correction: BEX4 inhibits the progression of clear cell renal cell carcinoma by stabilizing SH2D4A, which is achieved by blocking SIRT2 activity.

Correction: BEX4 inhibits the progression of clear cell renal cell carcinoma by stabilizing SH2D4A, which is achieved by blocking SIRT2 activity.

Journal: Oncogene

Published: January 22, 2025

BEX4 inhibits the progression of clear cell renal cell carcinoma by stabilizing SH2D4A, which is achieved by blocking SIRT2 activity.

BEX4 inhibits the progression of clear cell renal cell carcinoma by stabilizing SH2D4A, which is achieved by blocking SIRT2 activity.

Journal: Oncogene

Published: April 26, 2024

Deubiquitinating enzyme OTUD4 stabilizes RBM47 to induce ATF3 transcription: a novel mechanism underlying the restrained malignant properties of ccRCC cells.

Deubiquitinating enzyme OTUD4 stabilizes RBM47 to induce ATF3 transcription: a novel mechanism underlying the restrained malignant properties of ccRCC cells.

Journal: Apoptosis : an international journal on programmed cell death

Published: March 03, 2024

ScRNA-seq revealed the tumor microenvironment heterogeneity related to the occurrence and metastasis in upper urinary tract urothelial carcinoma.

ScRNA-seq revealed the tumor microenvironment heterogeneity related to the occurrence and metastasis in upper urinary tract urothelial carcinoma.

Journal: Cancer gene therapy

Published: December 13, 2023

UBE2N promotes cell viability and glycolysis by promoting Axin1 ubiquitination in prostate cancer cells.

UBE2N promotes cell viability and glycolysis by promoting Axin1 ubiquitination in prostate cancer cells.

Journal: Biology direct

Published: November 28, 2023

ARHGAP6 inhibits bladder cancer cell viability, migration, and invasion via β-catenin signaling and enhances mitomycin C sensitivity.

ARHGAP6 inhibits bladder cancer cell viability, migration, and invasion via β-catenin signaling and enhances mitomycin C sensitivity.

Journal: Human cell

Published: November 01, 2022

Qici Sanling Decoction Suppresses Glutamine Consumption and Bladder Cancer Cell Growth through Inhibiting c-Myc Expression.

Qici Sanling Decoction Suppresses Glutamine Consumption and Bladder Cancer Cell Growth through Inhibiting c-Myc Expression.

Journal: Journal of oncology

Published: October 17, 2021

Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway.

Deleted in liver cancer 1 suppresses the growth of prostate cancer cells through inhibiting Rho-associated protein kinase pathway.

Journal: Asian journal of urology

Published: May 25, 2021

Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Β-catenin pathway.

Qici Sanling decoction suppresses bladder cancer growth by inhibiting the Wnt/Β-catenin pathway.

Journal: Pharmaceutical biology

Published: August 13, 2019

High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation.

High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation.

Journal: Oncology letters

Published: October 26, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026